Dernière mise à jour: Août 17, 2026
Efficacité des perfusions intraveineuses de cellules souches dans le traitement des patients COVID-19
Stem cell therapy has emerged as a revolutionary treatment for diseases that were considered untreatable only a few years ago. Cellules souches mésenchymateuses dérivées du cordon ombilical (UCMSC) il a été démontré qu'ils réparent le foie endommagé, rein, cœur, pancréas, peau, cartilage, and cornea in animal models and several human trials. In addition to cellular replacement through regeneration, UCMSCs mediate through paracrine signaling pathways resulting in immune modulation. Clinical manifestations of coronavirus disease 2019 (COVID 19), are believed to arise from septic shock and cytokine storm that cause acute respiratory dysfunction and acute cardiac injury. There is presently no cure for the COVID-19 viral disease; cependant, multi-treatment strategies are being examined. During the past two months, four reports were published that suggest, cellules souches mésenchymateuses (MSC), owing to their powerful immunomodulatory ability, may prevent the cytokine storm and thus reduce the COVID-19 related morbidity. All studies reported that COVID-19 patients responded favorably to MSCs therapy. These reports, taken together with the previous successes of stem cell therapy in animal models, the investigators, a seven-institution consortium, propose to explore the efficacy of UCMSC treatment in COVID-19 patients at Jinnah hospital, Lahore. The investigators propose to administer UCMSCs in patients with acute pulmonary inflammation due to COVID-19 infection with moderate to severe symptoms. In the first cohort of 15 patients, UCMSCs will be administered with three intravenous infusions of 500,000 UCMSCs per Kg body weight each on days 1, 3, et 5. The second group of five patients serving as control will only receive standard treatment. During the 30-day post-infusion period, a battery of tests will be performed to evaluate the safety and efficacy of the UCMSCs treatment. In parallel, the investigators propose a comparative study to determine COVID-19 viral count by quantitative real-time PCR and through viral coat protein ELISA, developed in the investigator advisor lab (Docteur. Tauseef Butt, Progenra Inc. Philadelphie, USA) with the ultimate objective to locally developing a rapid diagnostic assay.
Examen de cas scientifiques
Souhaitez-vous savoir si les programmes cliniques actuels, développements récents en recherche, ou des approches émergentes peuvent être adapté à votre situation individuelle?
Partagez votre question avec notre équipe de recherche scientifique et recevez informations axées sur les domaines de recherche en cours qui peuvent être pertinent pour votre cas.
- Examen des informations que vous fournissez
- Informations pertinentes sur la recherche et les programmes cliniques
- Une réponse claire et adaptée à votre situation
Aucune obligation. Votre question sera examinée de manière confidentielle.
Informations pédagogiques et de recherche uniquement. Ce service ne constituer un avis médical, diagnostic, ordonnance, ou un personnalisé recommandation de traitement.
